BR112022016492A2 - Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2 - Google Patents

Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2

Info

Publication number
BR112022016492A2
BR112022016492A2 BR112022016492A BR112022016492A BR112022016492A2 BR 112022016492 A2 BR112022016492 A2 BR 112022016492A2 BR 112022016492 A BR112022016492 A BR 112022016492A BR 112022016492 A BR112022016492 A BR 112022016492A BR 112022016492 A2 BR112022016492 A2 BR 112022016492A2
Authority
BR
Brazil
Prior art keywords
cov
sars
rbd
subunit
ndv
Prior art date
Application number
BR112022016492A
Other languages
English (en)
Inventor
Stanlee Rojas Neyra Aldo
Ivette Calderon Mayo Katherine
Clemente Fernandez Diaz Manolo
Original Assignee
Farm Veterinarios Sac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farm Veterinarios Sac filed Critical Farm Veterinarios Sac
Publication of BR112022016492A2 publication Critical patent/BR112022016492A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2. a presente invenção refere-se à obtenção de duas vacinas vivas recombinantes ou vetorizadas de ndv que expressam a subunidade s1 e rbd da proteína s do sars-cov-2, que, quando aplicada por via intranasal em modelo animal de hamster, gera a produção de anticorpos neutralizantes contra sars- cov-2. a invenção mostra ainda que essas vacinas vivas são compatíveis para seu uso combinado entre si, para induzir a produção de anticorpos neutralizantes contra sars-cov-2 sem interferência cruzada substancial, indicando uma sinergia entre ambas vacinas, onde os vírus recombinantes de ndv (rndv-ls1-hn-rbd/sars-cov-2 (seq id no. 7) e rndv-ls1-s1-f/sars-cov-2 (seq id no. 13)), conseguem expressar a subunidade s1 e rbd da proteína s de sars-cov-2 em mamíferos.
BR112022016492A 2021-01-08 2022-01-04 Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2 BR112022016492A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PE2021000033A PE20210318A1 (es) 2021-01-08 2021-01-08 Composicion inmunogenica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2
PCT/IB2022/050031 WO2022149058A1 (es) 2021-01-08 2022-01-04 Composición inmunogénica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteína spike del sars-cov-2

Publications (1)

Publication Number Publication Date
BR112022016492A2 true BR112022016492A2 (pt) 2023-10-31

Family

ID=74855966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016492A BR112022016492A2 (pt) 2021-01-08 2022-01-04 Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2

Country Status (7)

Country Link
AR (1) AR124522A1 (pt)
BR (1) BR112022016492A2 (pt)
CO (1) CO2022010353A2 (pt)
EC (1) ECSP22064620A (pt)
MX (1) MX2022004220A (pt)
PE (1) PE20210318A1 (pt)
WO (1) WO2022149058A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016217B1 (ru) * 2005-12-02 2012-03-30 Маунт Синай Скул Оф Медсин Химерные вирусы, представляющие неприродные поверхностные белки, и их применение
WO2021229270A1 (es) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN112011521A (zh) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用

Also Published As

Publication number Publication date
PE20210318A1 (es) 2021-02-16
WO2022149058A1 (es) 2022-07-14
AR124522A1 (es) 2023-04-05
MX2022004220A (es) 2022-08-08
ECSP22064620A (es) 2022-09-30
CO2022010353A2 (es) 2022-08-09

Similar Documents

Publication Publication Date Title
BRPI0707300A8 (pt) Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
BR112017014219A2 (pt) vacinas à base de nanopartículas multivalentes
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
BRPI1015917A2 (pt) antígenos de rsv recombinantes.
BR112019021824A2 (pt) Vacinas contra a malária e anticorpos de ligação a esporozoítos de plasmódio
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
NZ627888A (en) Materials and methods for respiratory disease control in canines
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
BR112022019949A2 (pt) Vacina com base em vetor de poxvírus atenuado para proteção contra covid-19
BR112022022604A2 (pt) Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos
MX2019003156A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
Xu et al. Differential modulation of avian β-defensin and Toll-like receptor expression in chickens infected with infectious bronchitis virus
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
BR112022016507A2 (pt) Vacinas contra o coronavírus e métodos de uso
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
AR067830A1 (es) Proteinas streptococcus inmunogenicas
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
MX2022012251A (es) Vacuna universal contra la influenza usando arnm modificado con nucleósidos.
BR112015023738A2 (pt) vacinas de nucleoproteina influenza
CO2023015564A2 (es) Virus quimérico de la enfermedad de newcastle que expresa las proteínas hn y f del apmv
BR112022016492A2 (pt) Composição imunogênica viva recombinante que compreende o vírus da doença de newcastle (ndv) que expressa a subunidade s1 e o rbd da proteína spike do sars-cov-2
AR085800A1 (es) Vacuna de rinitis equina
MX2021011439A (es) Vacuna recombinante contra covid-19 para producir respuesta celular en individuos con inmunidad preexistente.
BR112022011422A2 (pt) Imunógenos para vírus da caxumba e do sarampo e seus usos